Early-Stage Non-Small Cell Lung Cancer: New Challenges with Immune Checkpoint Blockers and Targeted Therapies

Area of Science:

• Oncology
• Thoracic Surgery
• Pharmacology

Background:

• Tyrosine kinase inhibitors (TKIs) and immune checkpoint blockers (ICBs) have revolutionized early-stage non-small cell lung cancer (NSCLC) treatment.
• Targeted therapies like osimertinib (EGFR-mutated) and alectinib (ALK-positive) have improved outcomes in resected NSCLC.
• Recent data, including the LAURA trial, highlight TKI efficacy in unresectable stage III NSCLC, expanding treatment paradigms.

Purpose of the Study:

• To review current evidence on TKIs and ICBs in early-stage NSCLC.
• To discuss ongoing clinical trials investigating neoadjuvant/perioperative TKI and ICB therapies.
• To identify and address challenges in TKI and ICB utilization for NSCLC.

Main Methods:

• Comprehensive literature review of TKI and ICB applications in early-stage NSCLC.
• Analysis of data from pivotal trials (e.g., LAURA) and ongoing studies.
• Discussion of treatment challenges, including optimal duration, minimal residual disease (MRD) role, and biomarker development.

Main Results:

• TKIs (osimertinib, alectinib) and ICBs (atezolizumab, pembrolizumab, nivolumab) are approved for various early-stage NSCLC settings (adjuvant, neoadjuvant, perioperative).
• Significant improvements in prognosis are observed with these agents in specific patient subgroups.
• Numerous trials are evaluating novel TKI and ICB strategies, including perioperative use and combinations.

Conclusions:

• TKIs and ICBs represent a paradigm shift in early-stage NSCLC management, offering improved outcomes.
• Key challenges remain, including defining optimal treatment duration, integrating MRD assessment, and identifying predictive biomarkers.
• Further research is crucial to refine TKI- and ICB-based strategies for maximizing efficacy in early-stage NSCLC.